Lifting the Curtain on Healthcare's Most Expensive Drugs

The explosion of orphan drug treatments is only gaining steam as pharma and biotech stocks look to combine ground breaking science with longer exclusivity over patient populations and astronomically high prices. Because orphan disease patient populations are so small, from just a few hundred to a few thousand in the U.S., and the unmet need, pharma companies are given extra protection and can charge more for treatment. No drug is more expensive than Alexion's (Nasdaq: ALXN) PNH drug Soliris at over $400,000 per year to be taken in perpetuity, but payers accept high prices because of the limited demand.

Since the early 1980's there have been roughly 450 orphan drugs approved, but with another 450 or so in the pipeline the industry's excitement is obvious. Investors should be excited as well, given the strong performance of orphan drug stocks, for instance Alexion is up 700% over the last 5 years, BioMarin quadrupled thanks in part to Naglazyme's $365,000 price tag, and Shire (Nasdaq: SHPG) has seen nearly a 500% run coinciding with its growing orphan drug business. But it is important to stay disciplined and not get caught up in the excitement when picking orphan drug stocks.

In this episode of Where The Money Is, Motley Fool health care analysts David Williamson and Michael Douglass give investors the background of orphan drugs, what makes them different, the type of prices they charge and 2 rules for investing in orphan drug stocks. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3012147, ~/Articles/ArticleHandler.aspx, 9/5/2015 10:30:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated 13 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 3:59 PM
ALXN $171.98 Down -3.30 -1.88%
Alexion Pharmaceut… CAPS Rating: ***
BMRN $126.51 Up +0.06 +0.05%
BioMarin Pharmaceu… CAPS Rating: ****
SHPG $222.50 Up +0.43 +0.19%
Shire plc (ADR) CAPS Rating: ****